The field of gene therapy has reached a significant milestone with the NHS approval of exagamglogene autotemcel (exa-cel), a revolutionary gene-editing treatment for sickle cell disease (SCD). This cutting-edge therapy offers a potential functional cure, bringing hope to thousands of patients who have long endured the debilitating effects of the condition.
The Burden of Sickle Cell Disease
Sickle cell disease is a genetic blood disorder that primarily affects individuals of Black African and Black Caribbean heritage. The disease causes red blood cells to take on a sickle shape, leading to painful crises, organ damage, and a reduced life expectancy. Historically, treatment options have been limited to symptom management, frequent hospitalisations, and lifelong blood transfusions.
A Transformative Approach
Exa-cel, a one-time gene therapy, employs CRISPR gene-editing technology to modify a patient’s stem cells, enabling the production of functional haemoglobin. Clinical trials have demonstrated remarkable efficacy, with 96.6% of participants achieving a functional cure, meaning they remained free from severe pain crises.
In addition:
✅ Hospitalisation rates dropped significantly – all patients avoided hospital stays for at least one-year post-treatment.
✅ Long-term relief – nearly 98% continued to avoid hospitalisation even 3.5 years after receiving the therapy.
✅ Quality of life improvements – patients reported a drastic reduction in pain and crisis episodes.
A Milestone for the NHS and Advanced Therapies
The approval of exa-cel strengthens the NHS’s commitment to leading the adoption of advanced therapies, ensuring innovative treatments reach eligible patients quickly. NHS England has secured cost-effective access to exa-cel through the Innovative Medicines Fund, further reinforcing its strategic approach to funding breakthrough treatments.
Patients who qualify for exa-cel will be treated at specialist NHS centres in London, Manchester, and Birmingham, offering a new standard of care for those previously without therapeutic options.
The Future of Gene Therapy in Rare Diseases
The introduction of exa-cel highlights the growing potential of gene-editing therapies in treating rare and inherited disorders. With advancements in CRISPR technology, manufacturing capabilities, and regulatory approvals, we are witnessing a shift towards curative, one-time treatments rather than chronic disease management.
As gene therapy continues to evolve, what does this mean for the future of biologics and personalised medicine? Will we see wider adoption of CRISPR-based interventions for other rare diseases?
Back to News + Insights